Last Updated : May 8, 2025
Details
FilesGeneric Name:
brentuximab vedotin
Project Status:
Pending
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0381-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Brentuximab vedotin containing regimen (BrECADD) for newly diagnosed Hodgkin Lymphoma.
Anticipated Date:
Files
Last Updated : May 8, 2025